PMID- 7547080
OWN - NLM
STAT- MEDLINE
DCOM- 19951120
LR  - 20191031
IS  - 0921-299X (Print)
IS  - 0921-299X (Linking)
VI  - 8
IP  - 1
DP  - 1994
TI  - Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer 
      cells and interleukin-2 in the adoptive immunotherapy of patients with 
      malignancies.
PG  - 41-50
AB  - Clinical effects and side effects were studied in the adoptive immunotherapy of 
      patients bearing malignant diseases using human leukocyte antigen 
      (HLA)-mismatched allogeneic lymphokine-activated killer (LAK) cells. Allogeneic 
      LAK cells were induced from peripheral blood lymphocytes (PBL) of normal donors 
      by means of initial stimulation with pokeweed mitogen (PWM). Six of 15 patients 
      applied in the adoptive immunotherapy showed clinical effects such as partial or 
      complete regression of pulmonary metastasis, pleural effusion and primary tumor. 
      All pulmonary metastatic lesions were eliminated in one case by this adoptive 
      immunotherapy combined with chemotherapy. Generally toxic effects were chillness, 
      fever and general fatigue which were reversible, and no allergic side effects 
      occurred even though allogeneic LAK cells were injected frequently except one 
      patient who showed preshock like symptom accompanied with leukocytopenia and 
      continuous hypotension immediately after infusion but was finally rescued. In the 
      patients who received more than 10(11) of allogeneic LAK cells, anti-HLA class I 
      antibodies appeared without any evidence of autoantibody. However, immunological 
      side effects were never experienced after injection of allogeneic LAK cells even 
      when the anti-HLA class I antibodies appeared in the patients. Taken together, 
      allogeneic LAK cells could be considered as alternative therapy for patients with 
      malignancies who could not supply sufficient materials of autologous LAK cells.
FAU - Kimoto, Y
AU  - Kimoto Y
AD  - Department of Oncology, Osaka University Medical School, Japan.
FAU - Tanaka, T
AU  - Tanaka T
FAU - Tanji, Y
AU  - Tanji Y
FAU - Fujiwara, A
AU  - Fujiwara A
FAU - Taguchi, T
AU  - Taguchi T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Biotherapy
JT  - Biotherapy (Dordrecht, Netherlands)
JID - 8903031
RN  - 0 (HLA Antigens)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Adult
MH  - Cells, Cultured
MH  - Cytotoxicity, Immunologic
MH  - Female
MH  - Graft vs Host Reaction
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - *Immunotherapy, Adoptive/adverse effects
MH  - Interleukin-2/adverse effects/*therapeutic use
MH  - Killer Cells, Lymphokine-Activated/*immunology
MH  - Liver Neoplasms/secondary/therapy
MH  - Lung Neoplasms/secondary/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/immunology/*therapy
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 10.1007/BF01878120 [doi]
PST - ppublish
SO  - Biotherapy. 1994;8(1):41-50. doi: 10.1007/BF01878120.